CardiologyEducation/TrainingEmergency/TraumaGeriatricsMental HealthNephrology/UrologyPediatricsPopular PressWomen`s Health
		Search NurseLinx Archives
September 03, 2010 In Vitro and in Vivo Effects of Statins on Platelet Activating Factor and its Metabolism - Angiology Tsantila N et al. – Simvastatin with an intact lactone ring also inhibited PAF–activities, while incubation of human mesangial cells with it also resulted in decreased de novo PAF–biosynthesis. This suggests that these simvastatin–dependent effects are independent of its lactone ring. These new actions of statins should be further studied in PAF–implicated pathological conditions such as CVD, cancer, and renal disease.... Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia - Clinical Endocrinology Tan T et al. – Cabergoline is a highly effective medical treatment for patients with hyperprolactinaemia. There is an increased risk of valvular heart disease in patients receiving cabergoline for Parkinson's disease. This study examined whether cabergoline treatment of hyperprolactinaemia is associated with a greater prevalence of valvulopathy. The data demonstrates that there is no association between cabergoline treatment for hyperprolactinaemia and valvulopathy. This study therefore supports continued use of low–dose cabergoline for patients with hyperprolactinaemia.... Differential effects of TAK-442, a novel orally active direct factor Xa inhibitor, and ximelagatran, a thrombin inhibitor, on factor V-mediated feedback on coagulation cascade and bleeding - Thrombosis and Haemostasis Konishi N et al. – The results suggest that the differential effects of the two agents on FV–mediated amplification of thrombin generation may underlie the observation of a wider therapeutic window for TAK–442 than for ximelagatran.... A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents - Thrombosis and Haemostasis Wenaweser P et al. – Neither atorvastatin 40 mg daily nor fluvastatin 80 mg daily administered in combination with standard dual antiplatelet therapy following coronary drug–eluting stent implantation significantly interfere with the antiaggregatory effect of ASA and clopidogrel.... Plasma Renin Activity Predicts Blood Pressure Responses to (beta)-Blocker and Thiazide Diuretic as Monotherapy and Add-On Therapy for Hypertension - American Journal of Hypertension Turner ST et al. – Plasma renin activity and pretreatment blood pressure level predict blood pressure responses to atenolol and hydrochlorothiazide administered as mono– and as add–on therapy in men and women <65 years of age.... Argatroban in the management of heparin-induced thrombocytopenia - Vascular Health and Risk Management Babuin L et al. – Argatroban was evaluated as the anticoagulant therapy in 3 prospective, multicenter, open–label studies in HIT patients who underwent PCI. The studies were similar in design with respect to patient inclusion and exclusion criteria, the argatroban dosing regimen, and primary efficacy outcomes. The investigators performed a pooled analysis of these studies, which showed that most patients achieved a satisfactory outcome from the procedure and adequate anticoagulation.... Lack of Increase in Vancomycin Resistance of Pediatric Methicillin-Resistant Staphylococcus aureus Isolates From 2000 to 2007 - The Pediatric Infectious Disease Journal Zheng X et al. – The authors retrospectively studied 306 pediatric methicillin–resistant Staphylococcus aureus isolates collected in 2000/2001, 2003, 2005, and 2007 for possible vancomycin minimum inhibitory concentration change over time using Etest, agar dilution, and broth microdilution methods. Vancomycin MICs did not increase. Inducible clindamycin resistance declined significantly. Considerably different proportions of isolates with vancomycin MIC = 2 micro g/mL were identified by different laboratory methodologies, suggesting the need for caution in their interpretation and in comparing published data.... Risk of Potential Drug-Drug Interactions among Brazilian Elderly: A Population-Based, Cross-Sectional Study - Drugs & Aging Secoli SR et al. – Approximately one–quarter of the elderly population living in Sao Paulo could be taking two or more potentially interacting medicines. Polypharmacy predisposes elderly individuals to PDDIs. More than half of these drug combinations (57.6%) were part of commonly employed treatment regimens and may be responsible for adverse reactions that compromise the safety of elderly individuals, especially at home. Educational initiatives are needed to avoid unnecessary risks.... The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer - European Respiratory Review Armour AA et al. – IPASS showed that EGFR mutation was the strongest predictor of improved progression–free survival (mutation–positive subgroup hazard ratio (HR) 0.48, 95% CI 0.36–0.64; mutation–negative subgroup HR 2.85, 95% CI 2.05–3.98 with gefitinib versus carboplatin/paclitaxel as first–line therapy for advanced NSCLC. Important lessons for the development of future personalised medicines are discussed.... Pazopanib: In Advanced Renal Cell Carcinoma - BioDrugs Sanford M et al. – Pazopanib is an orally administered, multi–tyrosine kinase inhibitor that interrupts tumor growth in renal cell carcinoma. Oral pazopanib had an acceptable tolerability profile in patients with advanced renal cell carcinoma. Adverse events were common in pazopanib and placebo recipients and were mostly of mild to moderate severity.... More News...